Septin 9 (SEPT9) Gene Mutation Analysis
Colorectal cancer (CRC) is the third most common diagnosed cancer and the second leading cause of cancer-related deaths in men and women. Early detection is very important for disease management. Publication show that if detected in early localized stage, the five-year survival rate is above 90%, if detected when there has only been progression to regional tissues, five-year survival is as high as 70%. However, if detected late, after the cancer has spread to distant organs/tissues, five-year survival decreases below 15%. Therefore, screening for CRC is important and has been supported by published recommendations and guidelines.
Four types of test are currently available for CRC detection or screening, including fecal-based occult blood test (FOBT or FIT), blood tumor marker test, combined fecal DNA and FIT test, and imaging (colonoscopy).
Gene methylation has been associated with a variety of cancers and pre-cancers. Methylation of the SEPT9 promoter has been shown to be specific for CRC and has been suggested as a plasma marker for early CRC detection.
SEPT9 is a member of septin family, a group of scaffolding proteins that provide structural support during cell division. Therefore, methylation of SEPT9 promoter will directly affected SEPT9 expression affecting cytokinesis and promoting CRC carcinogenesis. There are two FDA cleared tests used for detection of methylated SEPT9. Both tests use the same PCR technology and have very similar claims.
ColoVantage (Quest Diagnostics) and Epi ProColon are both tests to detect SEPT9 in blood samples. They are both recommended as screening tests for adults over age 50, particularly those who are non-compliant with other screening protocol and/or do not want to have colonoscopy. A positive result with either test indicates the possibility of an increased risk for colorectal cancer and further evaluation with colonoscopy should be considered.
- Screening and early detection of colorectal cancer in patient defined as having an average risk of colorectal cancer
Negative for mutations analyzed (No pathogen variants detected)
Whole blood, EDTA (lavender-top) tube.
Separate and Transport plasma frozen.
Stability
- Room: Unacceptable
- Refrigerated: Unacceptable
- Frozen: 28 days
- Clin Chem, 2009, 55(7): 1337-46. [PMID: 19406918]
- Epigenomics. 2010 Aug;2(4):575-85. [PMID: 22121975]
- Clin Chem. 2008 Feb;54(2):414-23. [PMID: 18089654]
- PLOS ONE. 2008, 3(11):e3759. [PMID: 19018278]
- Mol Cancer Res. 2007, 5:153-163. [PMID: 17314273]
- BMC Med. 2011 Dec 14;9:133. [PMID: 22168215]
- Clin Chem. 2014, 60(9):1183-1191. [PMID: 24938752]
- PLOS ONE. 2014, 9(6):e98238. [PMID: 24901436]